0001712762 2024-01-01 2024-12-31 0001712762 2024-12-31 2024-01-01 2024-12-31 false 0001712762 PRE 14A bioAffinity Technologies, Inc. true <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board has adopted a clawback policy which requires the clawback of erroneously awarded incentive-based compensation of past or current executive officers awarded during the three full fiscal years preceding the date on which the issuer is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the federal securities laws. There is no fault or misconduct required to trigger a clawback.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While we do <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90F_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20240101__20241231_zGnkONj78Mkd">not</span> have a formal written policy in place with regard to the timing of awards of options in relation to the disclosure of material nonpublic information, the Compensation Committee does not seek to time equity grants to take advantage of information, either positive or negative, about our Company that has not been publicly disclosed. It has been our practice to grant equity awards to our officers and directors upon their appointment. We intend to issue equity grants to our officers and directors at the same time each year. It is our policy to grant our executive officers annual equity awards of restricted stock in the first quarter of each year and to grant our directors annual equity awards of restricted stock on July 1 of each year. Option grants, if any, are effective on the date the award determination is made by the Compensation Committee, and the exercise price of options is the closing market price of our common stock on the business day of the grant or, if the grant is made on a weekend or holiday, on the prior business day.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fiscal year ended December 31, 2025, we did not award any options to a named executive officer, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90F_eecd--AwardTmgHowMnpiCnsdrdTextBlock_c20240101__20241231_z4JUzyJ0mMCb">we did <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_z0cBDuKzPGra"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_907_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_zP9XPeKfJBZi">not</span></span> time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation</span>.</span> false we did <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_z0cBDuKzPGra"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_907_eecd--MnpiDiscTimedForCompValFlag_dbF_c20240101__20241231_zP9XPeKfJBZi">not</span></span> time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation false false